Abstract
Perhaps the most chronic complaint of childhood presenting to family practitioners is the infant with recurrent wheezing. Before one even gets to grip with the rational choice of medicines in this group, one has to make the difficult choice between asthma and viral-induced wheezing, coupled with the understanding that many children stop wheezing without any long-term medication. However, once a decision is made to treat, one then has to face two additional hurdles: the first is the difficulty in administering medication to this age group. The second, perhaps even more daunting, is that few medicines have been tested in clinical trials in infants. "Off-label" use is therefore often an unavoidable necessity. This short article will review how the World Health Organisation's P-drug process might be of help in this difficult selection task.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.